Innoventric, a pioneering Structural Heart medical device company, has successfully raised $28,500,000 in its latest funding round, marking a significant milestone in its mission to revolutionize cardiac care. Specializing in the innovative development of percutaneous heterotopic cross-caval solutions, Innoventric is focused on addressing Tricuspid Regurgitation and other right heart diseases that affect millions globally. This substantial investment will bolster the company’s research and development capabilities, enabling it to advance its cutting-edge technologies and clinical trials, which aim to transform treatment landscapes for patients suffering from debilitating cardiac conditions. With the funds, Innoventric plans to expedite the commercialization of its next-generation medical devices, ensuring they meet stringent regulatory standards while delivering enhanced outcomes for both patients and healthcare providers. The cardiovascular field is witnessing a surge in interest and technological advancements, and Innoventric’s groundbreaking work is poised to position it as a leader in interventional cardiology. The company’s commitment to innovation aligns closely with the urgent need for effective solutions, as current treatment options often fall short. Innoventric is excited to partner with its investors to bring about transformative changes in the way tricuspid regurgitation and right heart diseases are managed. As the team works diligently towards its vision, it aims to set new benchmarks in the MedTech industry, ultimately improving patient quality of life. Join us in following Innoventric’s journey as they embark on this exciting chapter, poised to make waves in the field of cardiovascular health. For more information about their groundbreaking solutions, please visit [Innoventric's website](http://www.innoventric.com). #TTVR #Cardiology #MedTech #InterventionalCardiology #heterotopic #crosscaval #medicaldevices
Innoventric Secures $28.5 Million in Series B Funding for Revolutionary Structural Heart Medical Devices
Recently funded · $28.5M Series bHealthcare
Get the full INNOVENTRIC company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
